[{"id":"d42429d0-899b-4f9f-a9fd-c90fa6b9a50e","acronym":"NRG-GY027","url":"https://clinicaltrials.gov/study/NCT05276973","created_at":"2022-03-14T14:54:04.422Z","updated_at":"2025-02-25T16:38:53.900Z","phase":"Phase 1","brief_title":"Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer","source_id_and_acronym":"NCT05276973 - NRG-GY027","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1","pipe":" | ","alterations":" HRD","tags":["PTEN • HRD • NF1 • AKT1 • TSC1 • AKT1S1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HRD"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • ipatasertib (RG7440)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 09/08/2022","start_date":" 09/08/2022","primary_txt":" Primary completion: 01/30/2025","primary_completion_date":" 01/30/2025","study_txt":" Completion: 01/30/2025","study_completion_date":" 01/30/2025","last_update_posted":"2025-02-07"},{"id":"79a21cb0-b80b-4f09-9b9e-bdba02cd1248","acronym":"IMPACT","url":"https://clinicaltrials.gov/study/NCT01505400","created_at":"2021-01-18T06:19:22.670Z","updated_at":"2025-02-25T16:58:29.958Z","phase":"","brief_title":"Integrated Molecular Profiling in Advanced Cancers Trial","source_id_and_acronym":"NCT01505400 - IMPACT","lead_sponsor":"University Health Network, Toronto","biomarkers":" EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1","pipe":"","alterations":" ","tags":["EGFR • HER-2 • PIK3CA • FGFR2 • STK11 • HRAS • PDGFRA • JAK2 • AKT1 • FGFR4 • CTNNB1"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 3026","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-03"},{"id":"f4599b74-514d-415f-a4c1-0ad32a88ef07","acronym":"A071401","url":"https://clinicaltrials.gov/study/NCT02523014","created_at":"2021-01-18T12:11:52.655Z","updated_at":"2025-02-25T13:11:46.229Z","phase":"Phase 2","brief_title":"Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients with Progressive Meningiomas","source_id_and_acronym":"NCT02523014 - A071401","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3","pipe":" | ","alterations":" PIK3CA mutation • PTEN mutation","tags":["PIK3CA • PTEN • CDKN2A • AKT1 • CCND1 • CCNE1 • PTCH1 • CDK4 • NF2 • SMO • CDK6 • CCND2 • CCND3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PIK3CA mutation • PTEN mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Verzenio (abemaciclib) • Truqap (capivasertib) • Erivedge (vismodegib) • GSK2256098"],"overall_status":"Recruiting","enrollment":" Enrollment 124","initiation":"Initiation: 09/28/2015","start_date":" 09/28/2015","primary_txt":" Primary completion: 01/01/2026","primary_completion_date":" 01/01/2026","study_txt":" Completion: 01/01/2028","study_completion_date":" 01/01/2028","last_update_posted":"2025-01-15"},{"id":"8c77c515-8fd7-47a1-b2a0-d210db442390","acronym":"","url":"https://clinicaltrials.gov/study/NCT00977574","created_at":"2021-01-18T03:48:50.533Z","updated_at":"2024-07-02T16:35:03.140Z","phase":"Phase 2","brief_title":"Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer","source_id_and_acronym":"NCT00977574","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" AKT1","pipe":"","alterations":" ","tags":["AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • carboplatin • paclitaxel • temsirolimus • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Ixempra (ixabepilone) • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar) • patupilone (EPO 906)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 349","initiation":"Initiation: 09/14/2009","start_date":" 09/14/2009","primary_txt":" Primary completion: 01/31/2015","primary_completion_date":" 01/31/2015","study_txt":" Completion: 03/06/2025","study_completion_date":" 03/06/2025","last_update_posted":"2024-05-17"},{"id":"7fd8451e-e40a-4b5b-98c2-c1a67ba94776","acronym":"","url":"https://clinicaltrials.gov/study/NCT04192981","created_at":"2021-01-18T20:26:03.024Z","updated_at":"2024-07-02T16:35:09.028Z","phase":"Phase 1","brief_title":"GDC-0084 With Radiation Therapy for People With PIK3CA-Mutated Solid Tumor Brain Metastases or Leptomeningeal Metastases","source_id_and_acronym":"NCT04192981","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3","pipe":"","alterations":" ","tags":["PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3CG • PIK3CD • PIK3CB • INPP4B • AKT2 • INPP5D • PIK3C3 • PIK3R2 • PIK3R3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paxalisib (GDC-0084)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 12/06/2019","start_date":" 12/06/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-04-17"},{"id":"bd0915a0-fd20-4277-b54e-97bf1a6410c3","acronym":"","url":"https://clinicaltrials.gov/study/NCT03452774","created_at":"2021-01-18T17:01:36.578Z","updated_at":"2024-07-02T16:35:14.464Z","phase":"","brief_title":"SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry","source_id_and_acronym":"NCT03452774","lead_sponsor":"Massive Bio, Inc.","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703","pipe":" | ","alterations":" HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation","tags":["EGFR • HER-2 • PD-L1 • KRAS • BRAF • ER • ALK • TP53 • TMB • FLT3 • ABL1 • NRAS • BRCA1 • BRCA2 • FGFR2 • PTEN • ROS1 • IDH1 • NTRK1 • BCL2 • IDH2 • NTRK3 • NTRK2 • STK11 • NPM1 • HRAS • DNMT3A • ERBB3 • RB1 • CLDN18 • PDGFRA • NF1 • JAK2 • NRG1 • POLE • AKT1 • PD-1 • CCND1 • MCL1 • KDR • PBRM1 • BAP1 • VEGFA • BCL6 • PDGFRB • PTCH1 • FGFR4 • MSH6 • CDK4 • MSH2 • CTNNB1 • MAP2K2 • FBXW7 • WT1 • ATRX • BRCA • RAF1 • TSC2 • CHEK2 • PD-L2 • ERBB4 • JAK1 • FANCA • TSC1 • MDM4 • POLD1 • CDK6 • CEBPA • PARP1 • AURKA • JAK3 • RICTOR • CHEK1 • GATA6 • MSH3 • TGFBR2 • GNAS • MYCL • AKT2 • CCND2 • CCND3 • CSF1R • MAP3K1 • ERCC4 • HDAC1 • PRDM1 • ZNF217 • CDKN1A • GATA3 • PARP2 • PARP3 • SDHA • ACVR1B • ZNF703"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 mutation • BAP1 mutation • AKT1 mutation • FGFR3 fusion • JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 50000","initiation":"Initiation: 01/01/2018","start_date":" 01/01/2018","primary_txt":" Primary completion: 12/01/2026","primary_completion_date":" 12/01/2026","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-03-15"},{"id":"21a8be08-eefa-4035-aec2-4a3752975586","acronym":"IPATunity130","url":"https://clinicaltrials.gov/study/NCT03337724","created_at":"2021-01-17T17:26:41.567Z","updated_at":"2024-07-02T16:35:15.265Z","phase":"Phase 3","brief_title":"A Study of Ipatasertib in Combination With Paclitaxel as a Treatment for Participants With PIK3CA/AKT1/PTEN-Altered, Locally Advanced or Metastatic, Triple-Negative Breast Cancer or Hormone Receptor-Positive, HER2-Negative Breast Cancer","source_id_and_acronym":"NCT03337724 - IPATunity130","lead_sponsor":"Hoffmann-La Roche","biomarkers":" HER-2 • PIK3CA • PTEN • AKT1","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PIK3CA • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 579","initiation":"Initiation: 01/06/2018","start_date":" 01/06/2018","primary_txt":" Primary completion: 01/04/2023","primary_completion_date":" 01/04/2023","study_txt":" Completion: 01/04/2023","study_completion_date":" 01/04/2023","last_update_posted":"2024-03-12"},{"id":"2638658d-5de1-4c1e-afa0-e9fef20584a0","acronym":"","url":"https://clinicaltrials.gov/study/NCT01327781","created_at":"2021-01-18T05:24:42.319Z","updated_at":"2024-07-02T16:35:17.724Z","phase":"Phase 1","brief_title":"Z-Endoxifen Hydrochloride in Treating Patients With Metastatic or Locally Recurrent Estrogen Receptor-Positive Breast Cancer","source_id_and_acronym":"NCT01327781","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K","pipe":" | ","alterations":" ER positive • HER-2 expression • EGFR expression","tags":["EGFR • HER-2 • ER • PGR • AKT1 • mTOR • IGF1R • NCOA3 • PI3K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 expression • EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Zonalta (Z-endoxifen hydrochloride)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 62","initiation":"Initiation: 03/25/2011","start_date":" 03/25/2011","primary_txt":" Primary completion: 03/05/2017","primary_completion_date":" 03/05/2017","study_txt":" Completion: 10/30/2024","study_completion_date":" 10/30/2024","last_update_posted":"2024-02-26"},{"id":"d65863ad-7efa-4719-a1a1-47fc18cfeebf","acronym":"iRetroBC","url":"https://clinicaltrials.gov/study/NCT06131424","created_at":"2023-11-14T22:15:41.310Z","updated_at":"2024-07-02T16:35:22.353Z","phase":"","brief_title":"NIS Study Determining Prevalence of HER2-low in Metastatic Breast Cancer Patients","source_id_and_acronym":"NCT06131424 - iRetroBC","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PIK3CA • BRCA1 • PTEN • ATM • AKT1","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative • PIK3CA mutation • HER-2 expression • ATM mutation • PALB2 mutation • ESR1 mutation • BRCA1 mutation + BRCA2 mutation","tags":["HER-2 • ER • PIK3CA • BRCA1 • PTEN • ATM • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative • PIK3CA mutation • HER-2 expression • ATM mutation • PALB2 mutation • ESR1 mutation • BRCA1 mutation + BRCA2 mutation"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 2700","initiation":"Initiation: 03/04/2024","start_date":" 03/04/2024","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-01-24"},{"id":"68ced0d1-5116-4b3d-8079-1a15f3e6de8f","acronym":"FAIM","url":"https://clinicaltrials.gov/study/NCT04920708","created_at":"2021-06-11T00:54:37.032Z","updated_at":"2024-07-02T16:35:31.322Z","phase":"Phase 2","brief_title":"Fulvestrant, Ipatasertib and CDK4/6 Inhibition in Metastatic ER+/HER2- Breast Cancer Patients Without ctDNA Suppression","source_id_and_acronym":"NCT04920708 - FAIM","lead_sponsor":"Royal Marsden NHS Foundation Trust","biomarkers":" HER-2 • ER • PIK3CA • PTEN • AKT1","pipe":" | ","alterations":" HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • ER positive + HER-2 negative • CDK4 mutation","tags":["HER-2 • ER • PIK3CA • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HER-2 negative • PIK3CA mutation • HER-2 mutation • ER positive + HER-2 negative • CDK4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • Verzenio (abemaciclib) • Kisqali (ribociclib) • fulvestrant • ipatasertib (RG7440) • Pegasys (pegylated interferon α -2a)"],"overall_status":"Recruiting","enrollment":" Enrollment 324","initiation":"Initiation: 12/28/2022","start_date":" 12/28/2022","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-10-27"},{"id":"ed87f07f-d94b-4782-87e1-520859d6cee3","acronym":"GERTRUDE","url":"https://clinicaltrials.gov/study/NCT05933395","created_at":"2023-07-06T16:10:21.285Z","updated_at":"2024-07-02T16:35:31.527Z","phase":"Phase 2","brief_title":"Genetically-informed Therapy for ER+ Breast Cancer Post-CDK4/6 Inhibitor","source_id_and_acronym":"NCT05933395 - GERTRUDE","lead_sponsor":"Dartmouth-Hitchcock Medical Center","biomarkers":" HER-2 • PIK3CA • PTEN • RB1 • AKT1 • mTOR • CDK4","pipe":"","alterations":" ","tags":["HER-2 • PIK3CA • PTEN • RB1 • AKT1 • mTOR • CDK4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e everolimus • Nerlynx (neratinib) • Piqray (alpelisib) • Verzenio (abemaciclib) • fulvestrant"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 10/10/2023","start_date":" 10/10/2023","primary_txt":" Primary completion: 10/01/2030","primary_completion_date":" 10/01/2030","study_txt":" Completion: 10/01/2031","study_completion_date":" 10/01/2031","last_update_posted":"2023-10-26"},{"id":"2fd38c52-b64b-4e26-aac4-6e079d9c3e0a","acronym":"","url":"https://clinicaltrials.gov/study/NCT05991947","created_at":"2023-08-15T19:10:06.072Z","updated_at":"2024-07-02T16:35:39.996Z","phase":"","brief_title":"Preliminary Experimental Study on Key Technologies for Early Screening of Gastric Cancer","source_id_and_acronym":"NCT05991947","lead_sponsor":"Zhejiang Cancer Hospital","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A","pipe":" | ","alterations":" KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • HRAS • CDKN2A • AKT1 • TOP2A • IL6 • RNF43 • CTNNB1 • FBXW7 • MUC16 • GNAS • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • BRAF mutation • FGFR2 mutation • RNF43 mutation • AKT1 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 1100","initiation":"Initiation: 12/01/2021","start_date":" 12/01/2021","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-08-15"},{"id":"6ed06cab-c7c7-450b-93d9-67848afd9e45","acronym":"CICLADES","url":"https://clinicaltrials.gov/study/NCT03318263","created_at":"2021-01-18T16:23:13.868Z","updated_at":"2024-07-02T16:35:40.862Z","phase":"","brief_title":"CIrCuLAting Dna ESr1 Gene Mutations Analysis","source_id_and_acronym":"NCT03318263 - CICLADES","lead_sponsor":"Institut de Cancérologie de Lorraine","biomarkers":" HER-2 • ER • PIK3CA • AKT1","pipe":" | ","alterations":" ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative","tags":["HER-2 • ER • PIK3CA • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PIK3CA mutation • ER mutation • ESR1 mutation • AKT1 mutation • ER positive + HER-2 negative"],"overall_status":"Completed","enrollment":" Enrollment 146","initiation":"Initiation: 12/07/2017","start_date":" 12/07/2017","primary_txt":" Primary completion: 12/22/2022","primary_completion_date":" 12/22/2022","study_txt":" Completion: 12/22/2022","study_completion_date":" 12/22/2022","last_update_posted":"2023-08-04"},{"id":"be4768d1-1e90-4d4e-9999-620c54f7b1c4","acronym":"","url":"https://clinicaltrials.gov/study/NCT03804255","created_at":"2021-01-18T18:48:15.229Z","updated_at":"2024-07-02T16:35:42.079Z","phase":"","brief_title":"Assessment of Current Biomarker Testing Practices for Common Solid Cancers in Precision Oncology in the Community Setting","source_id_and_acronym":"NCT03804255","lead_sponsor":"ECOG-ACRIN Cancer Research Group","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • MSI • PTEN • HRAS • AKT1","pipe":"","alterations":" ","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • PIK3CA • MSI • PTEN • HRAS • AKT1"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 01/08/2019","start_date":" 01/08/2019","primary_txt":" Primary completion: 05/29/2020","primary_completion_date":" 05/29/2020","study_txt":" Completion: 05/29/2020","study_completion_date":" 05/29/2020","last_update_posted":"2023-07-25"},{"id":"56cf2aa4-0bb8-4ec7-a2a3-ea438f302a37","acronym":"CAPItello-291","url":"https://clinicaltrials.gov/study/NCT04305496","created_at":"2021-01-18T20:52:48.632Z","updated_at":"2024-07-02T16:35:47.030Z","phase":"Phase 3","brief_title":"Capivasertib+Fulvestrant vs Placebo+Fulvestrant as Treatment for Locally Advanced (Inoperable) or Metastatic HR+/HER2- Breast Cancer","source_id_and_acronym":"NCT04305496 - CAPItello-291","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • ER • PIK3CA • PGR • PTEN • AKT1","pipe":" | ","alterations":" HER-2 negative • PGR expression","tags":["HER-2 • ER • PIK3CA • PGR • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e fulvestrant • Truqap (capivasertib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 818","initiation":"Initiation: 04/16/2020","start_date":" 04/16/2020","primary_txt":" Primary completion: 08/15/2022","primary_completion_date":" 08/15/2022","study_txt":" Completion: 06/07/2024","study_completion_date":" 06/07/2024","last_update_posted":"2023-05-29"},{"id":"d9d3567e-a116-4764-b0c4-18eb2c09592c","acronym":"","url":"https://clinicaltrials.gov/study/NCT02549989","created_at":"2021-01-18T12:20:10.264Z","updated_at":"2024-07-02T16:35:54.941Z","phase":"Phase 2","brief_title":"Study of LY3023414 for the Treatment of Recurrent or Persistent Endometrial Cancer","source_id_and_acronym":"NCT02549989","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3R2","pipe":" | ","alterations":" PTEN deletion","tags":["PIK3CA • PTEN • AKT1 • PIK3R1 • PIK3R2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN deletion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e samotolisib (LY3023414)"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 03/23/2022","primary_completion_date":" 03/23/2022","study_txt":" Completion: 03/23/2022","study_completion_date":" 03/23/2022","last_update_posted":"2023-02-22"},{"id":"c4d024fe-0ad9-4ccb-bdd3-007d1646b965","acronym":"GIM21","url":"https://clinicaltrials.gov/study/NCT05735392","created_at":"2023-02-21T16:01:47.579Z","updated_at":"2024-07-02T16:35:55.179Z","phase":"","brief_title":"Liquid Biopsy: Intercepting Mutational Trajectories of HER2 (Human Epidermal Growth Factor Receptor 2) Breast Cancer (GIM21 Trial)","source_id_and_acronym":"NCT05735392 - GIM21","lead_sponsor":"Consorzio Oncotech","biomarkers":" EGFR • HER-2 • PIK3CA • PTEN • AKT1 • PIK3R1 • MUC4","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • HER-2 mutation • PIK3R1 mutation","tags":["EGFR • HER-2 • PIK3CA • PTEN • AKT1 • PIK3R1 • MUC4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • PIK3CA mutation • HER-2 mutation • PIK3R1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine)"],"overall_status":"Completed","enrollment":" Enrollment 48","initiation":"Initiation: 11/07/2018","start_date":" 11/07/2018","primary_txt":" Primary completion: 01/12/2022","primary_completion_date":" 01/12/2022","study_txt":" Completion: 01/12/2022","study_completion_date":" 01/12/2022","last_update_posted":"2023-02-20"},{"id":"de090239-ac97-4a09-a8c1-e09e9af7bef0","acronym":"LUDOC II","url":"https://clinicaltrials.gov/study/NCT02518256","created_at":"2021-01-18T12:10:09.769Z","updated_at":"2024-07-02T16:36:04.422Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity","source_id_and_acronym":"NCT02518256 - LUDOC II","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 270","initiation":"Initiation: 05/01/2014","start_date":" 05/01/2014","primary_txt":" Primary completion: 12/31/2021","primary_completion_date":" 12/31/2021","study_txt":" Completion: 12/31/2021","study_completion_date":" 12/31/2021","last_update_posted":"2022-09-06"},{"id":"bb882abd-a09d-45b4-b16d-33846bd77bd9","acronym":"PIKNIC","url":"https://clinicaltrials.gov/study/NCT02506556","created_at":"2021-03-02T12:19:35.132Z","updated_at":"2025-02-25T15:42:30.490Z","phase":"Phase 2","brief_title":"Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast Cancer","source_id_and_acronym":"NCT02506556 - PIKNIC","lead_sponsor":"Peter MacCallum Cancer Centre, Australia","biomarkers":" EGFR • HER-2 • KRAS • ER • ALK • PIK3CA • PGR • NRAS • PTEN • HRAS • AKT1 • PIK3R1 • INPP4B • PI3K • PIK3R3","pipe":" | ","alterations":" KRAS mutation • ER positive • EGFR mutation • HER-2 negative • PIK3CA mutation • EGFR amplification • ALK mutation","tags":["EGFR • HER-2 • KRAS • ER • ALK • PIK3CA • PGR • NRAS • PTEN • HRAS • AKT1 • PIK3R1 • INPP4B • PI3K • PIK3R3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • ER positive • EGFR mutation • HER-2 negative • PIK3CA mutation • EGFR amplification • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib)"],"overall_status":"Completed","enrollment":" Enrollment 38","initiation":"Initiation: 09/07/2015","start_date":" 09/07/2015","primary_txt":" Primary completion: 10/26/2021","primary_completion_date":" 10/26/2021","study_txt":" Completion: 10/26/2021","study_completion_date":" 10/26/2021","last_update_posted":"2022-08-16"},{"id":"f70ef90a-fdc9-405b-b396-50a810ed6ef5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05273099","created_at":"2022-03-10T14:58:06.191Z","updated_at":"2024-07-02T16:36:13.173Z","phase":"","brief_title":"Molecular Biomarkers Predicting Early Development of Endometrial Carcinoma","source_id_and_acronym":"NCT05273099","lead_sponsor":"Università degli Studi di Ferrara","biomarkers":" EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A","pipe":" | ","alterations":" JAK3 mutation","tags":["EGFR • HER-2 • KRAS • BRAF • ALK • TP53 • PIK3CA • FLT3 • ABL1 • NRAS • FGFR2 • PTEN • IDH1 • IDH2 • FGFR3 • FGFR1 • STK11 • NPM1 • HRAS • CDKN2A • RB1 • PDGFRA • NOTCH1 • JAK2 • GNAQ • AKT1 • KDR • MLH1 • GNA11 • PTPN11 • SMAD4 • CTNNB1 • FBXW7 • CDH1 • SMARCB1 • ERBB4 • JAK3 • GNAS • CSF1R • HNF1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e JAK3 mutation"],"overall_status":"Recruiting","enrollment":" Enrollment 8","initiation":"Initiation: 03/01/2022","start_date":" 03/01/2022","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/01/2023","study_completion_date":" 12/01/2023","last_update_posted":"2022-04-12"},{"id":"93b982fb-7c66-4921-b195-8eee74c88fbc","acronym":"LOTUS ","url":"https://clinicaltrials.gov/study/NCT02162719","created_at":"2021-01-17T17:26:40.920Z","updated_at":"2024-07-02T16:36:33.527Z","phase":"Phase 2","brief_title":"A Study Assessing the Safety and Efficacy of Adding Ipatasertib to Paclitaxel Treatment in Participants With Breast Cancer That Has Spread Beyond the Initial Site, and the Cancer Does Not Have Certain Hormonal Receptors","source_id_and_acronym":"NCT02162719 - LOTUS ","lead_sponsor":"Genentech, Inc.","biomarkers":" PIK3CA • PTEN • AKT1","pipe":" | ","alterations":" PTEN-L","tags":["PIK3CA • PTEN • AKT1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN-L"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • ipatasertib (RG7440)"],"overall_status":"Completed","enrollment":" Enrollment 124","initiation":"Initiation: 08/19/2014","start_date":" 08/19/2014","primary_txt":" Primary completion: 06/07/2016","primary_completion_date":" 06/07/2016","study_txt":" Completion: 08/31/2019","study_completion_date":" 08/31/2019","last_update_posted":"2021-03-10"},{"id":"3104391b-e3f1-42cd-bf6a-12a8612992d6","acronym":"CUARTET","url":"https://clinicaltrials.gov/study/NCT04601441","created_at":"2021-01-19T20:30:33.227Z","updated_at":"2024-07-02T16:36:37.659Z","phase":"Phase 4","brief_title":"Study to Evaluate ctDNA of mCSPC Patients Receiving Apalutamide in Japan","source_id_and_acronym":"NCT04601441 - CUARTET","lead_sponsor":"Kindai University","biomarkers":" KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1","pipe":"","alterations":" ","tags":["KRAS • BRAF • TP53 • PIK3CA • BRCA1 • BRCA2 • PTEN • IDH1 • IDH2 • CDKN2A • RB1 • ARID1A • AKT1 • RUNX1 • ASXL1 • CCND1 • PALB2 • MLH1 • KMT2D • MSH6 • CDK4 • MSH2 • RNF43 • CDK12 • CTNNB1 • ERCC1 • ERCC2 • FBXW7 • KMT2C • FANCA • RAD51B • KDM6A • MDM4 • PIK3R1 • RAD51C • CDK6 • PIK3CB • SPOP • FOXA1 • GNAS • ZFHX3 • AKT2 • CHD1 • CUL1 • ERCC5 • FANCF • FOXP1 • ERCC4 • CDKN1B • ERCC3 • FANCD2 • FANCE • FANCG • HSD3B1 • ZBTB16 • FANCC • NCOA2 • NKX3-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e apalutamide"],"overall_status":"Recruiting","enrollment":" Enrollment 100","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 03/31/2025","primary_completion_date":" 03/31/2025","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2020-12-08"},{"id":"8e96cc7a-6dec-4aa5-96fd-2012bb5fe9bb","acronym":"LUDOC","url":"https://clinicaltrials.gov/study/NCT02062697","created_at":"2021-01-18T09:30:05.355Z","updated_at":"2024-07-02T16:36:49.646Z","phase":"","brief_title":"Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma and Their Premalignant Changes.","source_id_and_acronym":"NCT02062697 - LUDOC","lead_sponsor":"Medical University of Vienna","biomarkers":" EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A","pipe":" | ","alterations":" PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation","tags":["EGFR • KRAS • BRAF • TP53 • PIK3CA • NRAS • FGFR2 • PTEN • CDKN2A • ARID1A • AKT1 • KMT2D • RNF43 • CTNNB1 • FBXW7 • PIK3R1 • MLL2 • FAT3 • CSMD3 • PPP2R1A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PTEN mutation • ARID1A mutation • FGFR2 mutation • KMT2D mutation • CTNNB1 mutation • RNF43 mutation • AKT1 mutation • PIK3R1 mutation"],"overall_status":"Completed","enrollment":" Enrollment 50","initiation":"Initiation: 02/01/2012","start_date":" 02/01/2012","primary_txt":" Primary completion: 11/01/2018","primary_completion_date":" 11/01/2018","study_txt":" Completion: 11/01/2018","study_completion_date":" 11/01/2018","last_update_posted":"2020-02-25"},{"id":"f1721518-a42e-44fe-b635-b90fb571dc99","acronym":"MOLTHYSO","url":"https://clinicaltrials.gov/study/NCT04053114","created_at":"2021-01-18T19:52:23.740Z","updated_at":"2024-07-02T16:36:57.060Z","phase":"","brief_title":"MOLecular Characterization and Treatment of THYroid Carcinoma on Struma Ovarii","source_id_and_acronym":"NCT04053114 - MOLTHYSO","lead_sponsor":"Institut Bergonié","biomarkers":" ALK • HRAS • AKT1 • TERT • CTNNB1","pipe":" | ","alterations":" ALK translocation • TERT mutation • FGFR3 expression • CTNNB1 expression","tags":["ALK • HRAS • AKT1 • TERT • CTNNB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK translocation • TERT mutation • FGFR3 expression • CTNNB1 expression"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 12/01/2019","primary_completion_date":" 12/01/2019","study_txt":" Completion: 05/01/2020","study_completion_date":" 05/01/2020","last_update_posted":"2019-08-12"}]